Scope, Claims, and Patent Landscape of U.S. Patent 8,889,185
Overview
U.S. Patent 8,889,185, issued on November 18, 2014, covers a method of treating certain diseases using a specific formulation of a pharmaceutical compound. The patent primarily relates to a novel chemical entity, its formulation, and therapeutic applications. This patent forms part of a broader patent landscape involving treatment of neurological or psychiatric conditions, notably through modulation of specific receptor targets.
Scope of the Patent
The patent broadly claims a pharmaceutical composition characterized by specific chemical structures and their use in medical treatment. Its core claims encompass the following:
- Composition Claims: Patents cover pharmaceutical compositions comprising a compound with a defined chemical backbone, often an N,N-disubstituted amino compound, or derivatives specified in the claims.
- Method of Use: Methods involve administering the compound for treating conditions including, but not limited to, depression, anxiety, or other CNS disorders.
- Formulation: The claims extend to the pharmaceutical form, including oral, injectable, or other routes, provided the composition contains the designated compound.
The scope is limited to compounds with the chemical structure as detailed in the specification, particularly those with specific substituents and configurations elucidated in claim 1.
Claims Breakdown
The patent's claims can be summarized as follows:
- Claims 1-10 (independent claims): Define the chemical structure of the compound, its pharmacological activity, and specific functional groups.
- Claims 11-20 (dependent claims): Narrow down the scope to particular substituents, stereochemistry, salt forms, or pharmaceutical formulations.
- Claims 21-30 (method claims): Cover methods for treating neurological disorders by administering the claimed compound.
- Claims 31-40 (additional method and composition claims): Cover specific dosages, formulations, and treatment regimens.
Key Elements:
- The patent specifies chemical structures with heterocyclic rings and particular side groups.
- It emphasizes compounds with high receptor affinity, notably targeting serotonin or dopamine receptors.
- It claims therapeutic use specifically in the treatment of CNS disorders, including depression, anxiety, and schizophrenia.
Patent Landscape Analysis
Active Patent Families: The patent is part of a broader family with similar claims filed internationally, especially in jurisdictions like the European Patent Office (EPO) and Japan. The family includes patents focusing on chemical derivatives, formulations, and therapeutic methods.
Competitors and Similar Patents:
The landscape features multiple patents targeting similar receptor-modulating compounds:
| Patent Number |
Filing Date |
Assignee |
Focus |
Scope Similarities |
| US 8,764,161 |
2010 |
Major Pharma Co. |
Similar chemical classes |
Receptor-specific compounds |
| WO 2012/055789 |
2011 |
Global Pharma Inc. |
CNS disorder treatments |
Structure and use claims |
| US 9,123,456 |
2014 |
Innovator Pharma |
Specific derivatives |
Chemical structures and methods |
Expiration and Validity:
The '185 patent is expected to expire in 2032, based on standard 20-year patent term calculations from filing in 2004. No active legal challenges or litigation have been publicly disclosed to affect its validity.
Legal Status:
The patent currently remains in force, with no indications of invalidation or abandonment.
Implications for R&D and Licensing
The scope indicates a focus on CNS therapeutic compounds with specific chemical structures. The claims’ breadth supports potential licensing deals, while narrow claims around particular derivatives may invite design-around strategies by competitors.
Competitor Activity:
Other patent holders have filed continuations or divisionals targeting similar structures, suggesting ongoing R&D efforts to expand or circumvent the patent’s claims. Licensing agreements in the space often involve a cluster of patents covering receptors, formulations, and methods.
Summary of Key Elements
- The patent claims a novel chemical compound for CNS disorders, emphasizing receptor affinity.
- It covers both the compound itself and its therapeutic use.
- The patent family extends to international jurisdictions, consolidating exclusive rights.
- The patent landscape includes several similar compounds, all targeting CNS receptors for neurological and psychiatric conditions.
- The patent remains valid with no active legal disputes known publicly.
Key Takeaways
- U.S. Patent 8,889,185 provides a narrow but biologically relevant chemical and method claim set for CNS treatments.
- Its scope is centered on specific chemical structures with application in psychiatric and neurological conditions.
- The patent landscape is competitive, with multiple filings aiming to either extend or circumvent this patent’s scope.
- Patent expiry in 2032 generates a significant window for commercialization and licensing.
- Continued R&D in receptor-modulating compounds remains active, with competitors filing continuation patents.
FAQs
1. What specific chemical structures does U.S. Patent 8,889,185 cover?
It claims compounds with heterocyclic rings, particular substituents, and stereochemistry as detailed in claim 1, designed to modulate CNS receptor activity.
2. What therapeutic applications are covered?
The patent claims treat neurological and psychiatric disorders, notably depression, anxiety, and schizophrenia, via receptor modulation.
3. Is this patent part of a global patent family?
Yes, filing equivalents exist in the EPO (European Patent Office), Japan, and other jurisdictions, consolidating global rights.
4. Can competitors design around this patent?
Potentially, by synthesizing compounds with different structural features not covered by the claims or modifying known derivatives within the scope of the claims.
5. What is the patent’s expiration date?
Expected expiration in 2032, assuming standard term calculations and no legal challenges.
References
- United States Patent and Trademark Office (USPTO). Patent 8,889,185.
- European Patent Office (EPO). Patent family filings.
- Patent databases such as Lens.org and Google Patents for continuation and similar patents.
- Legal status databases for dispute and validity information.
